Clinical trials recruiting for Urothelial Carcinoma
29
Recruiting trials
41
US states with sites
18
Countries
3%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 13 |
| California | 11 |
| Tennessee | 9 |
| Florida | 8 |
| New York | 8 |
| Michigan | 7 |
| Virginia | 7 |
| Colorado | 5 |
| Illinois | 5 |
| Massachusetts | 5 |
| Georgia | 4 |
| New Jersey | 4 |
Top cities
Nashville, Tennessee 9Los Angeles, California 8San Antonio, Texas 8Houston, Texas 7New York, New York 6Dallas, Texas 5Fairfax, Virginia 5Boston, Massachusetts 4Chicago, Illinois 4Denver, Colorado 4
Self-screener
Recruiting trials
- A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- A Multicenter Cancer Biospecimen Collection Study
- A Phase 2 Clinical Study of ABSK061 and ABSK043
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
- A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
- Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
- DBC-664 in Adult Patients With Solid Tumors
- Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
- Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
- GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
- Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
- Ivonescimab in the Treatment of Multiple Advanced Tumors
- Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
- Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
- The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
- This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study)
Related conditions
Trials recruiting for Urothelial Carcinoma often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Colorectal cancer 1359Breast cancer 2239Prostate cancer 1234Pancreatic cancer 870Non-small cell lung cancer 507Renal cell carcinoma 28Melanoma 487Ovarian cancer 118Gastric cancer 91
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Urothelial Carcinoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.